• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia associated hypertension
This article is protected by copyright. All rights reserved
Source: Biotechnology and Applied Biochemistry - July 16, 2019 Category: Biochemistry Authors: Yogendra Singh, Vijaya Paul Samuel, Sunita Dahiya, Gaurav Gupta, Ritu Gillhotra, Anurag Mishra, Mahaveer Singh, Nagaraja SreeHarsha, Shiva Kumar Gubbiyappa, Murtaza M. Tambuwala, Dinesh Kumar Chellappan, Kamal Dua Tags: Review Article Source Type: research

Prediction Model for the Efficacy of Folic Acid Therapy on Hyperhomocysteinaemia based on genetic risk score methods.
Abstract No risk assessment tools for the efficacy of folic acid treatment for hyperhomocysteinaemia (HHcy) have been developed. We aimed to use two common genetic risk score (GRS) methods to construct prediction models for the efficacy of folic acid therapy on HHcy, and the best gene-environment prediction model was screened out. A prospective cohort study enrolling 638 HHcy patients was performed. We used logistic regression model to estimate the associations of two GRS methods with the efficacy. Performances were compared using area under the receiver operating characteristic curve (AUC). The simple count genet...
Source: The British Journal of Nutrition - April 1, 2019 Category: Nutrition Authors: Du B, Zhang C, Yue L, Ren B, Zhao Q, Li D, He Y, Zhang W Tags: Br J Nutr Source Type: research

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first ‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
In this study, we evaluated the effects of aflibercept in first‑line therapy with FOLFOX followed by maintenance with fluoropyrimidine. VELVET was a prospective, single‑arm multicenter phase II study (completed). Patients with previously untreated, unresectable, evaluable or measurable mCRC, with an age ≥18 years, and an ECOG performance status of 0‑2 received 6 cycles of modified FOLFOX7 (5‑FU/folinic acid and oxaliplatin) with aflibercept at 4 mg/kg every 2 weeks followed by maintenance therapy with fluoropyrimidine with aflibercept until disease progression or limiting toxicity. The reintroduction of oxa...
Source: International Journal of Oncology - February 1, 2019 Category: Cancer & Oncology Authors: Chibaudel B, Bachet JB, André T, Auby D, Desramé J, Deplanque G, Lecaille C, Louvet C, Tournigand C, Lebrun-Ly V, Dauba J, Lledo G, Garcia ML, Dubreuil O, Hamed NB, Meurisse A, Larsen AK, Tijeras-Raballand A, Bonnetain F, De Gramont A Tags: Int J Oncol Source Type: research

The modifying effect of the MTHFR genotype on the association between folic acid supplementation and pulse wave velocity: Findings from the CSPPT
ConclusionIn a subgroup of Chinese hypertensive patients who had received 5 ‐year antihypertensive therapy, increases in folate status were associated with higher reductions in PWV, and individuals with the CC genotype showed greatest PWV response to folic acid supplementation.
Source: Cardiovascular Therapeutics - January 28, 2019 Category: Cardiology Authors: Xin Yang, Minghua Zhang, Rensheng Song, Changfu Liu, Yong Huo, Geng Qian Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

The power of folic-acid: Supplements can slash a stroke by almost 75%
Researchers from Peking University found that adults with hypertension who take folic acid, alongside blood-pressure medication, every day for four years are 73 per cent less at risk of stroke.
Source: the Mail online | Health - May 7, 2018 Category: Consumer Health News Source Type: news

Effect of Smoking and Folate Levels on the Efficacy of Folic Acid Therapy in Prevention of Stroke in Hypertensive Men Clinical Sciences
Conclusions—Baseline folate levels and smoking status can interactively affect the risk of first stroke. Our data suggest that compared with never smokers, ever smokers may require a higher dosage of folic acid to achieve a greater beneficial effect on stroke. Our findings need to be confirmed by future randomized trials.Clinical Trial Registration—URL: https://www.clinicaltrials.gov. Unique identifier: NCT00794885.
Source: Stroke - December 22, 2017 Category: Neurology Authors: Ziyi Zhou, Jianping Li, Yaren Yu, Youbao Li, Yan Zhang, Lishun Liu, Yun Song, Min Zhao, Yu Wang, Genfu Tang, Mingli He, Xiping Xu, Yefeng Cai, Qiang Dong, Delu Yin, Xiao Huang, Xiaoshu Cheng, Binyan Wang, Fan Fan Hou, Xiaobin Wang, Xianhui Qin, Yong Huo Tags: Primary Prevention, Hypertension, Treatment, Cerebrovascular Disease/Stroke Original Contributions Source Type: research

Urine Arsenic and Arsenic Metabolites in U.S. Adults and Biomarkers of Inflammation, Oxidative Stress, and Endothelial Dysfunction: A Cross-Sectional Study
Conclusion: In a cross-sectional study of U.S. adults, we observed some positive associations of uAs and toenail As concentrations with biomarkers potentially relevant to CVD pathogenesis and inflammation, and evidence of a higher capacity to metabolize inorganic As was negatively associated with a marker of oxidative stress. https://doi.org/10.1289/EHP2062 Received: 14 April 2017 Revised: 13 November 2017 Accepted: 15 November 2017 Published: 15 December 2017 Address correspondence to S.F. Farzan, 2001 N. Soto St., Los Angeles, CA, 90032. Telephone: (323)-442-5101; Email: sffarzan@usc.edu Supplemental Material is ava...
Source: EHP Research - December 16, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Association between percent decline in serum total homocysteine and risk of first stroke
Conclusions: Percent lowering in tHcy was significantly associated with a reduction in first stroke risk in Chinese adults with hypertension, and if further confirmed, may serve as a useful indicator for folic acid treatment efficacy on stroke prevention. Clinicaltrials.gov identifier: NCT00794885.
Source: Neurology - November 13, 2017 Category: Neurology Authors: Huang, X., Li, Y., Li, P., Li, J., Bao, H., Zhang, Y., Wang, B., Sun, N., Wang, J., He, M., Yin, D., Tang, G., Chen, Y., Cui, Y., Huang, Y., Hou, F. F., Qin, X., Huo, Y., Cheng, X. Tags: Stroke prevention, All Clinical trials ARTICLE Source Type: research

Effects of Folic Acid Therapy on the New-Onset Proteinuria in Chinese Hypertensive PatientsNovelty and Significance Clinical Trials
In conclusion, enalapril–folic acid therapy, compared with enalapril alone, significantly reduced the development of proteinuria in diabetic patients with hypertension.Clinical Trial Registration—URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00794885.
Source: Hypertension - July 12, 2017 Category: Cardiology Authors: Youbao Li, Min Liang, Guobao Wang, Binyan Wang, Mingli He, Genfu Tang, Delu Yin, Xin Xu, Yong Huo, Yimin Cui, Fan Fan Hou, Xianhui Qin Tags: Clinical Studies, Diabetes, Type 1, Diet and Nutrition, Hypertension Original Articles Source Type: research

Meta-analysis of folic acid efficacy trials in stroke prevention: Insight into effect modifiers
Conclusions: Folic acid supplementation could reduce the stroke risk in regions without folic acid fortification, particularly in trials using a relatively low dosage of folic acid and with low vitamin B12 levels.
Source: Neurology - May 8, 2017 Category: Neurology Authors: Zhao, M., Wu, G., Li, Y., Wang, X., Hou, F. F., Xu, X., Qin, X., Cai, Y. Tags: Stroke prevention, All Cerebrovascular disease/Stroke, Clinical trials Randomized controlled (CONSORT agreement), All epidemiology ARTICLE Source Type: research

Folic acid therapy reduces the risk of mortality associated with heavy proteinuria among hypertensive patients
Objective: We aimed to evaluate whether proteinuria and estimated glomerular filtration rate (eGFR) levels can modify the efficacy of folic acid therapy on the risk of all-cause mortality among hypertensive patients in the China Stroke Primary Prevention Trial, a randomized, double-blind, and controlled trial. Methods: A total of 20 702 hypertensive patients without a history of major cardiovascular diseases were randomly assigned to a double-blind daily treatment of a single tablet containing 10-mg enalapril and 0.8-mg folic acid (n = 10 348), or 10-mg enalapril alone (n = 10 354). All-cause mortality, a pr...
Source: Journal of Hypertension - April 26, 2017 Category: Cardiology Tags: ORIGINAL PAPERS: Kidney Source Type: research

Folic acid supplementation and chronic kidney disease progression
In contrast to prior studies demonstrating no benefit or even increased harm from B vitamin supplementation in patients with chronic kidney disease, a large randomized trial from China recently demonstrated small but statistically significant reductions in the risk of first stroke and chronic kidney disease progression with the addition of folic acid to enalapril in adults with hypertension. Differences in the study population and study intervention may explain these discordant results.
Source: Kidney International - November 21, 2016 Category: Urology & Nephrology Authors: Christina M. Wyatt, J. David Spence Tags: Nephrology Digest Source Type: research

Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients Clinical Sciences
Background and Purpose—We sought to determine whether folic acid supplementation can independently reduce the risk of first stroke associated with elevated total cholesterol levels in a subanalysis using data from the CSPPT (China Stroke Primary Prevention Trial), a double-blind, randomized controlled trial.Methods—A total of 20 702 hypertensive adults without a history of major cardiovascular disease were randomly assigned to a double-blind daily treatment of an enalapril 10-mg and a folic acid 0.8-mg tablet or an enalapril 10-mg tablet alone. The primary outcome was first stroke.Results—The median treatment durat...
Source: Stroke - October 23, 2016 Category: Neurology Authors: Qin, X., Li, J., Spence, J. D., Zhang, Y., Li, Y., Wang, X., Wang, B., Sun, N., Chen, F., Guo, J., Yin, D., Sun, L., Tang, G., He, M., Fu, J., Cai, Y., Shi, X., Ye, P., Chen, H., Zhao, S., Chen, M., Gao, C., Kong, X., Hou, F. F., Huang, Y., Huo, Y. Tags: Clinical Studies, Diet and Nutrition, Primary Prevention, Hypertension, Ischemic Stroke Original Contributions Source Type: research

Pages: 1  2  3